Deitch E A
Department of Surgery, Louisiana State University Medical Center, Shreveport 71130.
Ann Surg. 1992 Aug;216(2):117-34. doi: 10.1097/00000658-199208000-00002.
Multiple organ failure (MOF) has reached epidemic proportions in most intensive care units and is fast becoming the most common cause of death in the surgical intensive care unit. Furthermore, in spite of the development of successive generations of new and more powerful antibiotics and increasing sophisticated techniques of organ support, our ability to salvage patients once MOF has become established has not appreciably improved over the last two decades. Clearly, new therapeutic strategies aimed at preventing or limiting the development of the physiologic abnormalities that induce organ failure are needed to improve survival in these critically ill patients. Based on our rapidly increasing knowledge of the mechanisms of MOF and the fruits of molecular biology, a number of new therapeutic approaches are in various stages of development. To effectively use these new therapeutic options as they become available, it is necessary to have a clear understanding of the pathophysiology of MOF. Thus, the goals of this review are to integrate the vast amount of new information on the basic biology of MOF and to focus special attention on the potential therapeutic consequences of these recent advances in our understanding of this complex and perplexing syndrome.
多器官功能衰竭（MOF）在大多数重症监护病房已呈流行态势，且正迅速成为外科重症监护病房最常见的死亡原因。此外，尽管新一代更强大的抗生素不断研发出来，器官支持技术也日益复杂，但在过去二十年里，一旦MOF确立，我们挽救患者的能力并未得到明显改善。显然，需要新的治疗策略来预防或限制引发器官衰竭的生理异常的发展，以提高这些重症患者的生存率。基于我们对MOF机制的快速增长的认识以及分子生物学的成果，一些新的治疗方法正处于不同的研发阶段。为了在这些新的治疗选择可用时有效地加以利用，有必要清楚了解MOF的病理生理学。因此，本综述的目的是整合关于MOF基础生物学的大量新信息，并特别关注我们对这一复杂且令人困惑的综合征的最新认识进展所带来的潜在治疗后果。
